share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Officer Roberts M Scot

SEC announcement ·  Feb 1 18:07
Summary by Moomoo AI
Altimmune, Inc.'s Chief Scientific Officer, M Scot Roberts, completed a series of transactions involving the company's common stock over the course of January 30 and 31, 2024. On January 30, Roberts exercised options to acquire 9,275 shares at no cost and subsequently sold 2,709 shares at $9.80 per share, resulting in a total market value of $26,548.20 for the disposed shares. The following day, Roberts acquired an additional 5,860 shares at a price of $2.69 per share. After these transactions, Roberts directly held a total of 32,850 shares of Altimmune common stock. Additionally, there are 15 shares held indirectly by Roberts' spouse.
Altimmune, Inc.'s Chief Scientific Officer, M Scot Roberts, completed a series of transactions involving the company's common stock over the course of January 30 and 31, 2024. On January 30, Roberts exercised options to acquire 9,275 shares at no cost and subsequently sold 2,709 shares at $9.80 per share, resulting in a total market value of $26,548.20 for the disposed shares. The following day, Roberts acquired an additional 5,860 shares at a price of $2.69 per share. After these transactions, Roberts directly held a total of 32,850 shares of Altimmune common stock. Additionally, there are 15 shares held indirectly by Roberts' spouse.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more